NEC has published a white paper “Toward Realization.” AI drug discovery development: A Comprehensive Process Workflow for Commercial Application of Personalized Cancer Vaccines”. In this white paper, we'll show you:
(1) A comprehensive process workflow that can be applied to a wide range of processes, from tumor sample collection to vaccine design, manufacturing, delivery, and administration;
(2) important aspects to consider in the workflow, and
(3) Advanced technology that contributes to the realization of workflows.
NEC aims to establish accurate, reliable, and comprehensive process workflows that utilize AI and security technologies, and will continue to take on the challenge of realizing new cancer treatments.
top News: GenAI Enabler Langdock raises $3M to improve workplace productivity with LLM
AI for cancer treatment
In recent years, expectations have been rising for personalized neoantigen cancer vaccines as a next-generation cancer treatment method. Personalized neoantigen cancer vaccine is a type of cancer immunotherapy that targets neoantigens that contain genomic mutations unique to each patient. NEC uses AI, one of its core technologies, to identify target neoantigens from each patient's genome information and is working to create personalized cancer vaccines.
This white paper proposes a comprehensive process workflow from design to administration of personalized cancer vaccines and the perspectives that should be discussed in this flow. Furthermore, we will introduce NEC's advanced ICT technology from these perspectives, and discuss the possibility of contributing not only to personalized cancer vaccines but also to the realization of various cancer treatment platforms by utilizing ICT technology. To do.
